title: Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA).
abstract: This brief review describes the potential non-glycaemic effects and benefits of glucagon like peptide 1 receptor agonists (GLP1RA). It lists various indications in which this class of drugs has been used, and explains the rationale behind this use. The potential uses of GLP1RA extend across the entire spectrum of endocrinology and metabolism, from hypothalamic obesity to non-alcoholic steatohepatitis (NASH) to polycystic ovary syndrome (PCOS). The article also discusses and addresses endocrine-related concerns related to the GLP1RAs.
authors.affiliation: Department of Endocrinology, 1Bharti Hospital, Karnal, 2All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: Department of Endocrinology, 1Bharti Hospital, Karnal, 2All India Institute of Medical Sciences, New Delhi, India.
authors.forename: Yashdeep
authors.initials: Y
authors.lastname: Gupta
mesh_terms: D001842:Bone and Bones / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D000077270:Exenatide; D005260:Female; D006066:Gonads / Q000187:drug effects; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications / Q000188:drug therapy; D054795:Incretins / Q000494:pharmacology* / Q000627:therapeutic use; D000069450:Liraglutide / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy; D009765:Obesity / Q000188:drug therapy / Q000209:etiology; D010053:Ovary / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D013737:Testis / Q000187:drug effects; D013961:Thyroid Gland / Q000187:drug effects; D014688:Venoms / Q000494:pharmacology* / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D054795:Incretins; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D000077270:Exenatide; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: Incretin therapy, Exenatide, Liraglutide, Exenatide QW.